白云山收购南京医药11.04%股份获批 交易额7.49亿元

财中社
Nov 17, 2025

  11月17日,白云山(600332/00874)发布公告,广州广药二期基金股权投资合伙企业(有限合伙)已收到国资主管单位广州医药集团有限公司的批复,同意以协议转让方式收购南京医药股份有限公司(600713)1.45亿股非限售股份(占南京医药股份总数11.04%)的股份,转让价款为7.49亿元。

  广药二期基金承诺自目标股份过户登记之日起18个月内不对外转让该股份,期间因上市公司送股、转增股本等事项而增加的股份亦遵循相同的锁定安排。

  2025年前三季度,白云山实现收入616.06亿元,归母净利润33.10亿元。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10